Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000321583 | SCV000338070 | uncertain significance | not provided | 2015-11-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001308077 | SCV001497512 | uncertain significance | Autosomal dominant limb-girdle muscular dystrophy type 1F | 2025-01-15 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 456 of the TNPO3 protein (p.Asn456Ser). This variant is present in population databases (rs371704560, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with TNPO3-related conditions. ClinVar contains an entry for this variant (Variation ID: 285167). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt TNPO3 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002519173 | SCV003734777 | uncertain significance | Inborn genetic diseases | 2022-08-17 | criteria provided, single submitter | clinical testing | The c.1367A>G (p.N456S) alteration is located in exon 11 (coding exon 11) of the TNPO3 gene. This alteration results from a A to G substitution at nucleotide position 1367, causing the asparagine (N) at amino acid position 456 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |